Welcome to our dedicated page for Positron news (Ticker: POSC), a resource for investors and traders seeking the latest updates and insights on Positron stock.
Positron Corporation (POSC) is a molecular imaging medical device company focused on PET and PET-CT imaging systems and clinical services for nuclear medicine providers across North America. The POSC news page on Stock Titan aggregates company announcements, transaction updates, and other disclosures that illustrate how Positron is executing its strategy in cardiac and oncology imaging.
Investors and healthcare professionals following POSC news can review releases on capital raises, such as equity financings used to support commercial expansion, product development, and regulatory initiatives. The company also issues news on its SEC reporting status, including the filing of a Form 10 registration statement and related steps toward operating as a reporting company under the Securities Exchange Act of 1934.
Another major category of Positron news involves product and sales activity. Recent announcements describe sales and agreements for Attrius PET and NeuSight PET-CT 64-slice scanners, multi-unit PET-CT orders, and placements through programs such as the NeuSight Prime Rental Program with cardiovascular diagnostic and treatment practices. These updates provide insight into demand for Positron’s cardiac PET and PET-CT systems among nuclear cardiology and nuclear medicine groups.
Positron also reports on strategic partnerships and corporate developments, including its industry partnership with MedAxiom, establishment of a new headquarters in the Buffalo–Niagara Falls region, and technology collaboration with Shenyang Intelligent Neuclear Technology Co., a subsidiary of Neusoft Medical Systems. By reviewing the POSC news feed, readers can track how the company is positioning its PET and PET-CT technologies, expanding relationships in cardiovascular care, and supporting adoption of cardiac PET imaging in clinical practice.
For ongoing research into POSC stock and business progress, users can return regularly to this page to see the latest company-issued news items and related market updates.
Positron (OTC: POSC), a leading molecular imaging medical device company, has joined the Cardiac PET Industry Coalition (CPIC). The coalition includes founding members such as Bracco Diagnostics, CDL Nuclear Technologies, and Siemens Healthcare, united to promote federal policies enhancing healthcare outcomes for cardiovascular disease patients. CPIC aims to improve access to cardiac PET diagnostics across the U.S., advocate for fair reimbursement policies, and educate healthcare providers and policymakers on the benefits of cardiac PET. Positron President Adel Abdullah emphasized the company's commitment to the coalition's goals and its role in advancing PET technology.
Positron (OTC: POSC) has secured exclusive North American rights to sell and distribute the NeuSight PET-CT 64 slice scanner through an agreement with Shenyang Intelligent Nuclear Medical Technology Co., a subsidiary of Neusoft Medical Systems. This award-winning scanner has FDA clearance for the US market and will be introduced in July 2024 for nuclear cardiac imaging. NeuSight PET-CT 64 offers advanced imaging for heart, tumor, and brain studies, combining anatomical and functional imaging with improved speed and accuracy. Positron aims to meet the increasing demand in the US, Canada, and Mexico, leveraging the system’s international success, with around 500 units sold globally.
Positron (OTC: POSC) has entered an agreement to acquire the FDA 510(k) clearance for the NeuSight PET-CT from Neusoft Medical Systems' subsidiary. This acquisition enables Positron to immediately market and sell the NeuSight PET-CT 64 slice imaging system and facilitates future FDA clearances for their Affinity PET-CT 4D 64 slice system. Adel Abdullah, President of Positron, emphasized that this milestone will significantly enhance their product line, which is vital for both oncology and nuclear cardiology. Positron aims to offer advanced PET-CT technology to healthcare practices, supported by Neusoft's extensive R&D expertise.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Positron Corporation (OTC: POSC) has entered a Clinical Study/Research Agreement with Ochsner Clinic Foundation for its new Affinity™ PET-CT 4D device. This agreement facilitates the collection of safety and efficacy data, crucial for obtaining an Investigational Device Exemption (IDE) from the FDA. The independent Institutional Review Board has approved all study procedures, allowing preparations for patient scans to begin post-IDE approval. The company aims for completion of the clinical study and FDA certification within 60 days, marking a significant step toward commercialization.
Positron Corporation (OTC: POSC) announces a collaboration with Dr. Robert Bober and Ochsner Health for a clinical study of its new Affinity PET-CT 4D imaging device. This FDA-compliant study, commencing mid-January 2023, aims to evaluate the device's image quality and performance in cardiac PET imaging. Dr. Bober's leadership is pivotal for gathering empirical data essential for marketing the system. Following completion and FDA 510k certification, Positron intends to commercialize the device in Q1 2023, targeting nuclear cardiology and oncology markets.
FAQ
What is the current stock price of Positron (POSC)?
What is the market cap of Positron (POSC)?
